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ABSTRACT Although the predominant Vibrio cholerae serotype in Pakistan is Ogawa and serotype 
Inaba is rare, there has been a significant increase in the isolation of Inaba in our referral laboratory in 
Karachi. This paper reports this observation and further analysis of previous cholera data from 1993 
to 2005 to assess the trend of occurrence and resistance pattern of V. cholerae strains. From January 
to September 2005, 245/3292 (7.4%) specimens yielded growth of V. cholerae. Of these, 243 were 
serotype Inaba, outnumbering serotype Ogawa. This recent Inaba strain is 100% resistant to co-
trimoxazole, 3% resistant to chloramphenicol and not resistant to ampicillin, tetracycline and ofloxacin. 
This sensitivity pattern is almost similar to that of the previous predominant serotype Ogawa. 
Accroissement de l’isolement du sérotype Vibrio cholerae O1 Inaba par rapport au sérotype 
Ogawa au Pakistan 
RÉSUMÉ Bien que le sérotype de Vibrio cholerae prédominant au Pakistan soit Ogawa et que le 
sérotype Inaba soit rare, on a constaté une augmentation significative de l’isolement d’Inaba dans 
notre laboratoire de référence de Karachi. Le présent article porte sur cette observation ainsi que 
sur une analyse plus poussée des précédentes données sur le choléra pour la période 1993-2005, 
afin d’évaluer la tendance de l’apparition et le schéma de résistance des souches de V. cholerae. De 
janvier à septembre 2005, 245/3292 (7,4 %) échantillons ont donné une culture de V. cholerae. Sur ces 
échantillons, 243 étaient du sérotype Inaba, donc plus nombreux que le sérotype Ogawa. Cette récente 
souche d’Inaba est résistante à 100 % au cotrimoxazole, à 3 % au chloramphénicol et non résistante à 
l’ampicilline, à la tétracycline et à l’ofloxacine. Ce profil de sensibilité est pratiquement identique à celui 
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Introduction
Vibrio cholerae, the causative agent of 
cholera, is subdivided into serogroups based 
on the somatic O antigen. Only the O1 
and O139 serogroups are reported to cause 
epidemic and pandemic disease. Each of the 
O1 biotypes can be further subdivided into 
2 major serotypes, Ogawa (VCO) and Inaba 
(VCI). Hikojima, a 3rd serotype also exists 
but is rare and unstable [1]. V. cholerae O1 
strains can undergo serotype conversion or 
switching between the Inaba and Ogawa 
serotypes related to a mutation in the wbeT 
region, a gene responsible for O1 antigen 
biosynthesis [2].
The predominant serotype in Pakistan 
is Ogawa and serotype Inaba is rare. Vari-
ous centres from Pakistan have published 
reports about V. cholerae isolates and in 
all of them isolation of Inaba serotypes are 
infrequent [3 –5]. In India and Bangladesh 
also the predominant serotype is Ogawa. 
However, 2 reports of the emergence of 
VCI have been published from India (Delhi 
and Chandigarh) showing increased isola-
tion of VCI in their cholera isolates [6,7]. 
This phenomenon is not yet reported from 
Pakistan.
Recently, however, there has been a sig-
nificant increase in the isolation of serotype 
Inaba in our laboratory, which has even 
outnumbered serotype Ogawa. This paper 
reports this observation and further analysis 
and comparison with previous cholera data 
at our institution to assess the trends of 
occurrence and resistance pattern of V. 
cholerae Ogawa and Inaba strains.
Methods
Setting
This descriptive study was conducted dur-
ing 1993–2005 at Aga Khan University, 
a tertiary care centre located in Karachi, 
Pakistan. The microbiology laboratory of 
the university receives specimens from both 
inpatients and outpatients from clinics and 
hospitals within the city and all over the 
country.
Specimen selection
All stool samples yielding growth of V. 
cholerae were selected from both inpatients 
and outpatients. Data was retrieved from a 
centralized computer database. Duplicate 
specimens from the same patients were 
excluded.
Microbiological methods
All stool samples for the isolation of V. 
cholerae were plated on tellurite taurocho-
late gelatin agar (TTGA) and incubated at 
37 ºC. In addition samples were inoculated 
in alkaline peptone water (APW) and after 
6 hours of incubation at 37 ºC were further 
subcultured on TTGA. After 24 hours of 
incubation, suspect colonies from TTGA 
were confirmed as V. cholerae using stand-
ard methods [8]. Serogroups were identified 
by slide agglutination with polyvalent anti-
sera for Ogawa and Inaba strains (Murex 
Diagnostic Limited), and for serogroup 
O139 (Dienka Sieken Co. Limited, Japan). 
Antimicrobial susceptibility testing was 
performed by Kirby Bauer disc sensitivity 
technique on Mueller–Hinton agar [9]. An-
tibiotics that were tested included ampicillin 
(10 μg), tetracycline (30 μg), cotrimoxazole 
(1.25/23.75 μg), chloramphenicol (30 μg) 
and ofloxacin (5 μg). The zone sizes (mm) 
for resistant (R), indeterminate (I) and sen-
sitive (S) strains were defined as follows: 
for ampicillin (R if ≤ 13, I if 14–16, S if ≥ 
17), for tetracycline (R if ≤ 14, I if 15–18, S 
if ≥ 19), for co-trimoxazole (R if ≤ 10, I if 
11–15, S if ≥ 16), for chloramphenicol (R if 
≤ 12, I if 13–17, S if ≥ 18) and for ofloxacin 
(R if ≤ 12, I if 13–15 S if ≥ 16). Escherichia 
coli ATCC25922 was used as the control.
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Statistical analysis
Data was entered and analysed using SPSS. 
P values were calculated using the t-test for 
2 independent samples. 
Results
From January to September 2005 a total 
of 3290 stool samples were received for 
culture at Aga Khan University laboratory. 
Of these 245 (7.4 %) yielded growth of V. 
cholerae. The total number of V. cholerae 
serotype Inaba (VCI) strains isolated were 
243 which greatly outnumbered serotype 
Ogawa (VCO) (2 strains). 
Over the period 1993–2005 the fre-
quency of isolation of VCI varied from year 
to year (Figure 1). However, there was a 
significant upsurge in the years 2004–05. 
In 2004, isolation of VCI was first observed 
in the month of November and there was 
an increase in the trend of isolation of VCI 
over the months. 
The mean age of patients with VCO 
was 20 years compared with 23 years for 
patients with VCI (P = 0.06). 
This recent VCI strain was 100% resist-
ant to cotrimoxazole, 3% resistant to chlo-
ramphenicol and not resistant to ampicillin, 
tetracycline and ofloxacin (Figure 2a). This 
susceptibility pattern was very similar to 
the previous predominant serotype Ogawa 
(Figure 2b). 
Discussion
This is the first report of increased isolation 
of serotype Inaba from Pakisatan. We have 
evaluated the data of Aga Khan University 
laboratory for the past 13 years and this 
increased pattern of VCI was never seen 
before. In a previous report by Jabeen et al., 
apart from predominant serotype Ogawa, 
there were increased numbers of cholera 
cases related to O139 serotype during the 
years 1993–1994 and 2000–2003 [3]. How-
Figure 1 Distribution of Vibrio cholerae, serotypes Ogawa (VCO) and Inaba (VCI)
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Figure 2a Antibiotic resistance of Vibrio cholerae, serotype Ogawa. AMP = ampicillin (10 µg), 
C = chloramphenicol (30 µg), OFX = ofloxacin (5 µg), TE = tetracycline (30 µg), SXT = co-
trimoxazole (1.25/23.75 µg)
Figure 2b Antibiotic resistance of Vibrio cholerae, serotype Inaba. AMP = ampicillin (10 µg), 
C = chloramphenicol (30 µg), OFX = ofloxacin (5 µg), TE = tetracycline (30 µg), SXT = co-
trimoxazole (1.25/23.75 µg)
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ever, serotype Ogawa was never overtaken 
by any other serotype as it was in 2005 by 
VCI. 
Two recent communications from India 
have reported the predominance of VCI in 
their cholera strains. One report was from 
Delhi in which 52% VCI were isolated in 
the year 2004, outnumbering VCO, the 
predominant strain in the past [6]. Taneja 
et al. from Chandigarh have reported the 
emergence of VCI in north India from a 
border security force camp [7].
In previous years, the isolation of VCI 
was rare and the most recent predominant 
outbreak was observed in 1989 in Calcutta 
[10]. Later, there were sporadic reports 
of outbreaks of VCI; one was from Ma-
lawi in 1990 which affected Mozambican 
refugees causing 1931 cases [11], another 
outbreak was in 1991 in which 8 patients 
in New Jersey, United States of America, 
developed cholera due to VCI after eating 
crabmeat [12]. Another outbreak of 12 
cholera cases caused by VCI was reported 
from Hong Kong in 1994, which was linked 
with consumption of seafood [13]. A report 
of an outbreak from southern India in 1996 
reported 13 nontoxigenic strains of VCI 
isolated from patients [14]. However, none 
of the above reports suggested continuous 
transmission, as in our study.
In 1984, there was a reported outbreak 
of nosocomial cholera involving 11 cases of 
VCI in southern Thailand [15]. A history of 
receiving tube-fed liquid diets was signifi-
cantly more common among cholera cases 
than in matched controls. Cases were also 
significantly more likely than controls to 
be on oral antacid medication, which could 
increase the risk of infection by neutralizing 
gastric acidity. In our hospital, however, 
we have not seen any case of nosocomial 
cholera.
The susceptibility pattern of our recent 
VCI isolates is more-or-less similar to the 
previously predominant serotype Ogawa. 
Increased resistance to cotrimoxazole sug-
gests the possibility of the presence of the 
SXT element, which is a self-transmissible, 
chromosomally integrated genetic element 
which carries cross-resistance to sulfam-
ethoxazole, trimethoprim, streptomycin and 
furazoloidine [16]. However, we did not test 
the latter 2 antibiotics in our study. Another 
study by Garg et al. also reported that the 
antibiogram and pulsed-field gel electro-
phoresis pattern of their current VCI strains 
were similar to that of the prevailing VCO 
strains, suggesting seroconversion due to 
mutation in the wbeT region [17]. We sug-
gest that there has been a serotype switching 
between the prevailing VCO strain and the 
current VCI strain due to mutation in the 
wbeT region, possibly because of immune 
pressure in the Pakistani population. How-
ever, we have not confirmed this fact as we 
have not performed molecular analysis of 
our VCI isolates. Quinolone resistance in 
V. cholerae has never been reported from 
Pakistan and 100% of our cholera isolates 
were sensitive to ofloxacin. However Das 
et al. from Delhi, India have reported that 
18% of their VCI isolates were resistant to 
ciprofloxacin [6].
The mean age of both VCI and VCO 
patients was similar, involving a younger 
age group. This again suggests serotype 
conversion as the same age group is af-
fected in both cases. This is in contrast to 
the outbreaks of VCO139 in Pakistan in 
1993–94 and 2000–01 in which an older age 
group was affected [3].
In conclusion, we are reporting for the 
first time increased isolation of VCI from 
Pakistan and suggest that these VCI strains 
are wbeT mutants from the previously pre-
dominant VCO and presumably have arisen 
as a result of selection due to the immune 
response against VCO in the Pakistani 
population. However, molecular analysis is 
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needed, as done by Garg et al. in Calcutta 
[17], to confirm our hypothesis. The ef-
fective transmission of this strain in the 
community suggests a decreased immune 
response in the population against this mu-
tant VCI strain. Government intervention 
and active health education campaigns on 
water and food safety and personal hygiene 
are immediately required to reduce the risk 
of a major public health disaster as this 
strain has been involved in many outbreaks 
of cholera in recent months. 
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Since 2005, the re-emergence of cholera has been noted in parallel 
with the ever-increasing size of vulnerable populations living in unsani-
tary conditions. Cholera remains a global threat to public health and 
one of the key indicators of social development. While the disease is 
no longer an issue in countries where minimum hygiene standards are 
met, it remains a threat in almost every developing country. The num-
ber of cholera cases reported to WHO during 2006 rose dramatically, 
reaching the level of the late 1990s. A total of 236 896 cases were 
notified from 52 countries, including 6311 deaths, an overall increase 
of 79% compared with the number of cases reported in 2005. This in-
creased number of cases is the result of several major outbreaks that 
occurred in countries where cases have not been reported for several 
years. It is estimated that only a small proportion of cases – less than 
10% – are reported to WHO. The true burden of disease is therefore 
grossly underestimated.
Source: WHO Fact sheet No. 107, revised September 2007 
(http://www.who.int/mediacentre/factsheets/fs107/en/index.html)
